诺泰生物
(688076)
| 流通市值：82.01亿 | | | 总市值：119.45亿 |
| 流通股本：1.46亿 | | | 总股本：2.13亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 355,815,137.72 | 1,033,548,079.03 | 709,466,382.95 | 400,781,544.83 |
| 营业收入 | 355,815,137.72 | 1,033,548,079.03 | 709,466,382.95 | 400,781,544.83 |
| 二、营业总成本 | 268,734,197.03 | 827,280,234.64 | 576,242,770.64 | 338,329,296.68 |
| 营业成本 | 116,478,624.19 | 403,395,372.22 | 278,907,360.19 | 169,991,448.23 |
| 税金及附加 | 705,184.14 | 7,201,629.17 | 4,775,484.72 | 3,231,593.8 |
| 销售费用 | 11,485,845.29 | 57,625,282.51 | 45,803,256.69 | 31,874,039.07 |
| 管理费用 | 70,571,854.29 | 222,579,291.53 | 153,608,141.7 | 89,592,707.44 |
| 研发费用 | 66,247,412.85 | 124,889,236.61 | 85,401,759 | 39,857,882.16 |
| 财务费用 | 3,245,276.27 | 11,589,422.6 | 7,746,768.34 | 3,781,625.98 |
| 其中:利息费用 | 6,347,691.06 | 16,085,329.99 | 11,061,070.99 | 7,042,250.32 |
| 其中:利息收入 | 1,262,960.83 | 6,207,703.28 | 5,129,449.7 | 3,845,919.24 |
| 加:公允价值变动收益 | - | 257,516.79 | -3,391,536.99 | -2,773,494.43 |
| 加:投资收益 | 173,464.72 | 2,903,701.2 | 2,149,880.62 | 931,449.26 |
| 资产处置收益 | - | 176,417.14 | 95,202.3 | 95,202.3 |
| 资产减值损失(新) | -6,142,181.86 | -28,892,606.29 | -16,686,621.06 | -12,621,093.23 |
| 信用减值损失(新) | -3,559,938.47 | -5,240,686.62 | -5,514,334.11 | -527,577.41 |
| 其他收益 | 3,267,875.41 | 14,193,608.3 | 11,194,078.97 | 6,607,984.24 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 80,820,160.49 | 189,665,794.91 | 121,070,282.04 | 54,164,718.88 |
| 加:营业外收入 | 69,733.2 | 554,638.78 | 442,094.24 | 233,688.19 |
| 减:营业外支出 | 439,183.07 | 17,093,559.71 | 6,665,396.06 | 6,522,762.02 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 80,450,710.62 | 173,126,873.98 | 114,846,980.22 | 47,875,645.05 |
| 减:所得税费用 | 15,885,785.67 | 7,674,212.02 | 24,507,607.11 | 8,024,400.26 |
| 六、净利润 | 64,564,924.95 | 165,452,661.96 | 90,339,373.11 | 39,851,244.79 |
| 持续经营净利润 | 64,564,924.95 | 165,452,661.96 | 90,339,373.11 | 39,851,244.79 |
| 归属于母公司股东的净利润 | 66,326,817.02 | 162,936,105.25 | 91,712,811.54 | 41,852,470.85 |
| 少数股东损益 | -1,761,892.07 | 2,516,556.71 | -1,373,438.43 | -2,001,226.06 |
| (一)基本每股收益 | 0.31 | 0.76 | 0.43 | 0.2 |
| (二)稀释每股收益 | 0.3 | 0.76 | 0.43 | 0.2 |
| 八、其他综合收益 | - | -24,617,700 | - | - |
| 归属于母公司股东的其他综合收益 | - | -24,617,700 | - | - |
| 九、综合收益总额 | 64,564,924.95 | 140,834,961.96 | 90,339,373.11 | 39,851,244.79 |
| 归属于母公司股东的综合收益总额 | 66,326,817.02 | 138,318,405.25 | 91,712,811.54 | 41,852,470.85 |
| 归属于少数股东的综合收益总额 | -1,761,892.07 | 2,516,556.71 | -1,373,438.43 | -2,001,226.06 |
| 公告日期 | 2024-04-23 | 2024-03-29 | 2023-10-21 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |